Home
This site is intended for healthcare professionals

Latest Advances in Hemophilia A Joint Care

15th Oct 2025
9:30 - 10:15pm (GMT)
15th Oct 2025
9:30 - 10:15pm (GMT)
Hosted on MedAll
Attendance certificate available
This event has ended. Similar events
Free
Online

Description

This program is supported by an independent education grant from Bayer. This online education program has been designed for healthcare professionals in the United States only.

In this online CME course, leading experts Guy Young, MD and Susan Knight, PT explore strategic approaches to preserve joint health in patients with mild to moderate hemophilia A:

  • Initiate timely prophylaxis: Identify patients with mild or moderate hemophilia A who may benefit from early Factor VIII prophylaxis to prevent progressive arthropathy.
  • Personalize treatment plans: Apply pharmacokinetic–guided dosing and activity-level assessment to tailor prophylaxis regimens for individual bleeding risk and lifestyle.
  • Implement proactive joint surveillance: Employ physical examination techniques, patient-reported outcomes, and imaging modalities (e.g., musculoskeletal ultrasound) to detect subclinical joint damage and guide interventions.

Accreditation: 0.75 AMA PRA Category 1 Credit™

Who Should Watch

  • Hematologists
  • Hemophilia Specialists
  • Hemophilia Treatment Center (HTC) Team Members
  • Nurse Practitioners in Bleeding Disorders
  • Physical Therapists
  • Physician Assistants in Bleeding Disorders
  • Other HCPs Involved in Joint Health Preservation

Presented by

Guy Young, MD – is a pediatric hematologist-oncologist specializing in hemophilia and other bleeding and clotting disorders. He is the Director of the Hemostasis and Thrombosis Center and Clinical Coagulation Laboratory at Children's Hospital Los Angeles. Dr. Young is also a Professor of Pediatrics at the Keck School of Medicine of USC. He is known for his work in developing and implementing preventative treatment strategies for hemophilia and for his research into novel therapies for bleeding and clotting disorders in children.

Susan Knight PT, PCS - Susan graduated from Mount St Mary’s College in 1991. Susan is the Clinical Director of the Children's Hospital Residency Program and has extensive experience managing student clinical education for the Rehabilitation Department. Susan has clinical expertise in evaluation and treatment of infants/preschoolers, persons with bleeding disorders, thrombophilia, and cerebral palsy.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Bayer.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Faculty

  • Guy Young, MD
  • Susan Knight PT, PCS

Disclosures

Dr Guy Young has disclosed financial relationships within the past 24 months with the following ineligible companies: Genetech/Roche, Sanofi, CSL Behring, Pfizer, and Hema Biologics. These relationships include consulting/speaker roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Young does not intend to discuss non-FDA uses of drug products and/or device.

Susan Knight PT, has disclosed financial relationships within the past 24 months with the following ineligible companies: Sanofi. These relationships include advisory board roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Susan Knight does not intend to discuss non-FDA uses of drug products and/or device.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™.

Physician Assistants

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program

Participation Costs

There is no cost to participate in this program.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

  1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
  2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Learning objectives

After completing this activity, the participant should be better able to:

Initiate timely prophylaxis in patients with mild to moderate hemophilia A to prevent joint deterioration:

  • Identify patients with mild or moderate hemophilia A who may benefit from early initiation of prophylaxis.
  • Explain the clinical evidence supporting early FVIII prophylaxis to reduce long-term joint complications.
  • Implement strategies to overcome delayed treatment initiation in real-world care settings.

Personalize hemophilia A treatment based on bleeding phenotype, activity level, and lifestyle:

  • Assess individual patient risk factors, including activity level and bleeding history, to guide treatment personalization.
  • Apply pharmacokinetic concepts and available tools to tailor prophylaxis regimens.
  • Adapt treatment plans in response to changes in patient lifestyle, preferences, or clinical outcomes.

Implement practical approaches for monitoring joint health in patients with non-severe hemophilia A:

  • Recognize the importance of routine joint surveillance, even in the absence of overt bleeding symptoms.
  • Utilize physical exams, patient-reported outcomes, and imaging to detect early signs of joint damage.
  • Integrate joint health monitoring into multidisciplinary care plans to support early intervention and joint preservation.
View all

Similar events and on demand videos

 
15th Oct 2025
9:30 - 10:15pm (GMT)
Hosted on MedAll
Attendance certificate available
This event has ended. Similar events
Free
Online